Vietnam's stock market sees highest single-day net foreign capital inflow in six years

This article was automatically generated using Dow Jones technology. Shares of Vanguard FTSE Emerging Markets ETF were flat at $60.62 Tuesday on what proved to be an overall favorable trading session for the U.S. stock market, with the S&P 500 Index rising 0.6% to 7,818.93. This was the fund's third consecutive day of gains. The ETF's shares closed 1.5% below the 52-week high of $61.53 seen on September 4, 2026. Trading volume was 4,661,177, compared to the 65-day average trading volume of 7,016,590. As of October 5, the fund's net asset value totaled $60.76 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:37 ET (20:37 GMT)

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Novavax Inc. shed 9.9% to $11.32 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.4% to 27,599.79 and the Dow Jones Industrial Average rising 0.5% to 51,521.28. Novavax Inc. closed 15.4% below its 52-week high of $13.39, which the company achieved on October 5th. The stock underperformed when compared to some of its peers, as Johnson & Johnson rose 0.7% to $254.78, Pfizer Inc. rose 0.3% to $27.50, and Merck & Co. Inc. rose 1.72% to $141.94. Trading volume totaled 19.3 million, compared to the 50-day average of 5.3 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:33 ET (20:33 GMT)

Evogene will hold a special general meeting of shareholders in Rehovot, Israel on Nov. 10, 2026. Shareholders will vote on electing Oz Adler and Dr. Adi Zuloff-Shani to the board. Ballots will also cover the election of Itay Maroz and Shahar Zadok, subject to approval of a cooperation agreement. The meeting will also vote on a cooperation agreement between Evogene and L.I.A. Pure Capital and Invest-Pro Shukai Hon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004722), on October 06, 2026, and is solely responsible for the information contained therein.